Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China

Abstract

Approximately a third of Chinese patients with schizophrenia in primary care receive APP. Further examination of the rationale and appropriateness of APP and its alternatives is warranted.